Skip to content

Value of MRI CSF Flowmetry in Assessment of Grey Zone Hydrocephalic Patients

Value of MRI CSF Flowmetry in Assessment of Grey Zone Hydrocephalic Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04060810
Enrollment
10
Registered
2019-08-19
Start date
2019-08-31
Completion date
2021-03-31
Last updated
2019-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydrocephalus

Brief summary

To evaluate accuracy of (MRI) cerebrospinal fluid flowmetry after shunt operation in patients with borderline (grey zone) hydrocephalus.

Detailed description

Hydrocephalus could be defined as disturbance of formation, flow or absorption of CSF. We encounter some challenging cases with intermittent non specific symptoms as delayed milestones and headache with concomitant imaging showing dilated ventricular system, so we find ourselves hesitating to take the decision of surgical intervention to put shunt or not, therefore MRI CSF flowmetry gives us a chance to overcome this problem. Phase contrast MR imaging is a rapid, simple and non-invasive technique which is sensitive to even small CSF flows, and can be used to evaluate CSF flow both qualitatively and quantitatively. CSF flow measurement at the suspected level of obstruction gives reliable and reproducible results for more accurate diagnosis and can be used to guide therapeutic decisions in a more reliable manner, and follow up post treatment outcome. With the CT and magnetic resonance imaging (MRI) techniques, it is possible to localize with accuracy the exact site of blockage of flow to CSF. Hence classification is as follows: The hydrocephalus may be due to 1) overproduction of CSF 2) obstructive 3) absorption defect. Depending on the exact aetiology, a secondary classification could be added under the following headings: 1) congenital, 2) acquired, eg; traumatic inflammatory, neoplastic, and degenerative . Bypassing the site of obstruction to CSF flow by diverting the CSF from ventricular cavity to a site where it is readily absorbed is the basic principle underlying the treatment of hydrocephalus. Extensive range of complications has been reported for shunting for hydrocephalus. They could be classified as mechanical or flow-related complications as CSF over drainage leading to subdural hematoma, subdural collections, low-pressure headaches cranial deformity, and asymmetrical drainage can lead to trapping or isolation of a part of a ventricular system. The slit ventricular syndrome is a complication related to absorption. Besides, ascites, loculations, hydrocele, perforation of the stomach, large and small bowel are also described. The success rates of shunt operation for hydrocephalus depend on the age of the patient and the reason why the shunt is needed. Generally, there is around a 50% failure rate for ventriculoperitoneal shunts.

Interventions

OTHERMR CSF flowmetry

MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients with borderline hydrocephalus * Clinically:suspicious and non specific symptoms as * Headache * Macrocranium * Vomiting * Gait instability * Dementia * Urine incontinence. * delayed milestone. * Radiologicaly: dilated ventricular system.

Exclusion criteria

* Documented or clinically and radiologically evident cases of hydrocephalus * Patients known to have contraindications for MRI, e.g. an implanted magnetic device, pacemakers or claustrophobia.

Design outcomes

Primary

MeasureTime frameDescription
Decompressive changes in CT brain2 monthsCT brain showing decompression of the ventricular system in response to ventriculoperitoneal shunt

Contacts

Primary ContactMohammad Mohammad
mohamed011353@med.aun.edu.eg01005663647

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026